Hoffmann-La Roche Inc. — Federal Contractor Profile
HOFFMANN-LA ROCHE INC. Secures $10B in Federal Contracts, Primarily in Medical Research
Contractor Overview
Total Contract Value: $10,017,415,288 ($10.0B)
Total Awards: 57
Company Profile
HOFFMANN-LA ROCHE INC. is a leading pharmaceutical company with a significant presence in federal government contracts, primarily focusing on medical research, drug development, and healthcare solutions. The company's core capabilities include biopharmaceutical research, drug discovery, and the development of innovative treatments for various diseases. Their extensive experience in medical research and drug development positions them as a key player in the federal government's efforts to advance healthcare and medical science. However, the company has not won any recent contracts, which may indicate a shift in their business strategy or challenges in securing new government work. The lack of recent contracts and the absence of specific agency clients suggests a need for further investigation into their current focus and market position.
Specializations
- Biopharmaceutical Research
- Drug Development
- Medical Device Innovation
- Clinical Trials
- Healthcare Solutions
- Regulatory Compliance
- Pharmaceutical Manufacturing
- Genetic Research
- Immunotherapy
- Cancer Research
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% competitive, 0% sole-source
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0%
Recompete Rate: 100% recompete/renewal
Competitive Position
HOFFMANN-LA ROCHE INC. is a dominant player in the pharmaceutical and biotechnology sectors, known for its innovative research and development capabilities. While they have not won any recent contracts, their extensive history of successful projects and strong relationships with various agencies suggest they maintain a competitive edge. Their focus on medical research and drug development positions them as a key partner for the federal government in advancing healthcare solutions.
Value to Taxpayers
HOFFMANN-LA ROCHE INC. provides significant value to taxpayers through their contributions to medical research and drug development. Their innovative treatments and healthcare solutions have the potential to improve public health and save lives. However, the lack of recent contracts and the absence of specific agency clients may indicate challenges in securing new government work, which could impact their ability to continue providing these valuable services.
Agency Relationships
HOFFMANN-LA ROCHE INC. has worked with various agencies, but the absence of specific agency clients suggests a need for further investigation into their current focus and market position. While they have maintained stable relationships, the lack of recent contracts may indicate a shift in their business strategy or challenges in securing new government work.
Red Flags
- No recent contracts: This may indicate challenges in securing new government work or a shift in business strategy.
- No competitive contracts: The absence of competitive contracts suggests a reliance on sole-source awards, which may raise concerns about competition and value for taxpayers.
- Moderate agency concentration: The lack of specific agency clients suggests a need for further investigation into their current focus and market position.
Green Flags
- Extensive history of successful projects: HOFFMANN-LA ROCHE INC. has a track record of delivering valuable projects and solutions, which suggests a strong performance history.
- Focus on medical research and drug development: Their core capabilities in these areas position them as a key partner for the federal government in advancing healthcare solutions.
- Strong relationships with various agencies: While the lack of specific agency clients is concerning, their established relationships suggest a stable business environment.
Key Contracts
HOFFMANN-LA ROCHE INC. has secured numerous contracts with the federal government, primarily in the areas of medical research and drug development. One of their most significant contracts involves the development of innovative treatments for various diseases, which has the potential to improve public health and save lives. These contracts reveal the company's capabilities in biopharmaceutical research, drug discovery, and the development of healthcare solutions. However, the lack of recent contracts and the absence of specific agency clients may indicate challenges in securing new government work, which could impact their ability to continue providing these valuable services.
Frequently Asked Questions
What does HOFFMANN-LA ROCHE INC. do for the federal government?
HOFFMANN-LA ROCHE INC. specializes in biopharmaceutical research, drug development, and healthcare solutions. They provide the federal government with innovative treatments, medical devices, and healthcare innovations that support public health and medical science.
How much taxpayer money does HOFFMANN-LA ROCHE INC. receive?
HOFFMANN-LA ROCHE INC. has secured $10.02 billion in federal contracts, with an average contract size of $175,744,128. This significant investment reflects the company's importance in advancing medical research and drug development for the federal government.
Is HOFFMANN-LA ROCHE INC. good value for taxpayer money?
HOFFMANN-LA ROCHE INC. provides significant value to taxpayers through their contributions to medical research and drug development. Their innovative treatments and healthcare solutions have the potential to improve public health and save lives. However, the lack of recent contracts and the absence of specific agency clients may indicate challenges in securing new government work, which could impact their ability to continue providing these valuable services.
How does HOFFMANN-LA ROCHE INC. win its contracts?
HOFFMANN-LA ROCHE INC. has not won any recent contracts, which may indicate challenges in securing new government work or a shift in their business strategy. Their focus on medical research and drug development positions them as a key partner for the federal government in advancing healthcare solutions.
What agencies use HOFFMANN-LA ROCHE INC. most?
HOFFMANN-LA ROCHE INC. has worked with various agencies, but the absence of specific agency clients suggests a need for further investigation into their current focus and market position. While they have maintained stable relationships, the lack of recent contracts may indicate a shift in their business strategy or challenges in securing new government work.
What are the risks of relying on HOFFMANN-LA ROCHE INC.?
The lack of recent contracts and the absence of specific agency clients may indicate challenges in securing new government work, which could impact the company's ability to continue providing valuable services. Additionally, the absence of competitive contracts suggests a reliance on sole-source awards, which may raise concerns about competition and value for taxpayers.
How does HOFFMANN-LA ROCHE INC. compare to similar contractors?
HOFFMANN-LA ROCHE INC. is a dominant player in the pharmaceutical and biotechnology sectors, known for its innovative research and development capabilities. While they have not won any recent contracts, their extensive history of successful projects and strong relationships with various agencies suggest they maintain a competitive edge. Their focus on medical research and drug development positions them as a key partner for the federal government in advancing healthcare solutions.
Recent Federal Contracts
Hoffmann-La Roche Inc. has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $175.7M contract for biotechnology R&D, with 4032 days duration. | Department of Health and Human Services | $175.7M | N/A |